Neurodegenerative Diseases
Conditions
Brief summary
In terms of the diagnostic technology of brain neurodegenerative diseases, the injection of positron tracers into the human body, so that it can combine with the corresponding protein, and show its distribution through PET imaging is a mature technology in the industry. At present, several research groups around the world are working on the development and clinical efficacy evaluation of their respective tau imaging agent compounds.This clinical research project intends to display the abnormal changes of tau protein in living brain through \[18F\]PM-PBB3 PET imaging, which is a second-generation tracer further optimized on the basis of \[11C\]PBB3, and has the advantages of closer binding to tau protein entanglement and less non-specific binding than similar imaging agents. Better image quality and a wider range of clinical applications.
Interventions
DIAGNOSTIC_TEST18F-PBB3 PET/CT scan
Patients with suspected neurodegeneration underwent PET/CT scan after injection of 370MBq (10 mCi)18F-FDG to observe for TAU deposition.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
49 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* Between 45 and 90 years old; No gender limitation. Brain MRI supported the diagnosis of neurodegeneration, and there was no evidence of other neurological diseases. Informed consent signed in person by the subject or his legal guardian or caregiver.
Exclusion criteria
* Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood system, tumor, endocrine, respiratory, immune deficiency, and other serious diseases. Received an experimental drug or device within 1 month (whose efficacy or safety is unclear). patients who were unwilling to undergo PET/CT scans. pregnancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic Performance | Through study completion, an average of 1 year | Diagnostic performance including sensitivity, specificity, accuracy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Stage | Through study completion, an average of 1 year | Clinical stage changed by 18F-PBB3 PET/CT compared to 18F-FDG PET/CT. |
Countries
China
Contacts
Primary ContactChenhao Jia, M.D.
Outcome results
None listed